Research programme: janus kinase inhibitors - Rigel Pharmaceuticals/Aclaris Therapeutics

Drug Profile

Research programme: janus kinase inhibitors - Rigel Pharmaceuticals/Aclaris Therapeutics

Alternative Names: R 333; R 548; R 723

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics; Rigel Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia areata
  • Discontinued Haematological malignancies

Most Recent Events

  • 23 Mar 2016 Aclaris Therapeutics has patent protection for Janus Kinase inhibitor in the Us and outside the US (Aclaris Therapeutics 10-K; March 2016)
  • 23 Mar 2016 Aclaris Therapeutics has patents pending for Janus kinase inhibitors in the US and outside the US (Aclaris Tehrapeutics 10-K; March 2016)
  • 07 Jan 2016 Preclinical trials in Alopecia areata in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top